Acceleron to Host Conference Call and Webcast to Review MEDALIST and BELIEVE Phase 3 Trial Presentations of Luspatercept at the 60th American Society of Hematology Annual Meeting

Acceleron Pharma Inc. XLRN, a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 a.m. EST to review the MEDALIST and BELIEVE Phase 3 trial presentations of luspatercept at the 60^th American Society of Hematology (ASH) Annual Meeting and Exposition taking place on December 1-4, 2018 in San Diego, California.

Guest Presenters:

• Alan F. List, M.D., President and CEO of Moffitt Cancer Center, Senior member in the Department of Malignant Hematology and the Experimental Therapeutics Program, Professor of Internal Medicine and Oncology at the University of South Florida Morsani College of Medicine
• Maria Domenica Cappellini, M.D., Chief of the Internal Medicine Unit, Professor of Internal Medicine, University of Milan, Chief of the Rare Disease Centre at the Policlinico Hospital IRCCS Foundation Ca' Granda, Milan, Italy

Participants can access the live conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and referring to the "Acceleron ASH 2018 Conference Call."

The live webcast can be accessed under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com.

A replay of the webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181127005181/en/